Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
WILLIAM R. SCHIEF · SCRIPPS RESEARCH INSTITUTE, THE · 2022 · $901,223 — Induction of broadly neutralizing antibodies (bnAbs) is a critical unmet goal of HIV vaccine development. BnAb 10E8 is of particular interest as a vaccine lead due to its (1) very high breadth, (2) low number of mutations required to develop broad neutralization, (3) low auto-reactivity, (4) expe…
Elias Sayour · UNIVERSITY OF FLORIDA · 2022 · $560,034 — Project Summary Immunotherapy has shown profound benefit for adult patients but has yet to be fully unlocked for pediatric solid tumors such as osteosarcoma (OSA) where a significant percentage of children/adolescents succumb due to the presence of lung metastasis. OSA, like many poorly tumor immuno…
Joseph Edgar Craft · YALE UNIVERSITY · 2022 · $648,095 — PROJECT SUMMARY A novel vaccine for Lyme disease Acquired resistance to Ixodes scapularis, commonly known as “tick resistance”, can prevent transmission of Borrelia burgdorferi, the Lyme disease agent. We have shown that tick resistance can be generated in guinea pigs (1) repeatedly exposed to I. s…
David M Allman · UNIVERSITY OF PENNSYLVANIA · 2022 · $203,125 — Project summary Plasma cells that secrete antibodies against self-antigens pose a considerable threat to human health. Moreover, because many plasma cells are exceptionally long-lived, strategies are needed to deplete long-lived plasma cells (LLPCs) that secrete pathogenic antibodies. This project c…
Koichi Araki · CINCINNATI CHILDRENS HOSP MED CTR · 2022 · $454,637 — CD8 T cells play an important role in controlling viral infections as well as intracellular bacterial and parasitic infections. It is now clear that CD8 T cells are also involved in immunity against tumors and there is considerable interest in cancer immunotherapy that stimulates CD8 T cell response…
Daniel F. Hoft · SAINT LOUIS UNIVERSITY · 2022 · $741,275 — Abstract Influenza is responsible for significant morbidity and mortality worldwide every year and causes severe pandemics when new strains evolve that have not previously circulated in humans. The high viral mutation rate necessitates that new vaccines be generated based on the prevalence of circul…
Ronald G Collman · UNIVERSITY OF PENNSYLVANIA · 2022 · $4,562,625 — CFAR Overview ABSTRACT This competing renewal application for the Penn Center for AIDS Research (CFAR) builds on an outstanding record of dynamic scientific leadership, organizational structure, resources and infrastructure that advance HIV/AIDS research across the integrated campus of the Universit…
MICHAEL ANDREW FISCHBACH · STANFORD UNIVERSITY · 2022 · $794,261 — PROJECT SUMMARY/ABSTRACT Eliciting or suppressing an adaptive immune response has become central to oncology, autoimmunity, and infectious disease. Checkpoint inhibitors have revolutionized the treatment of cancer, while TNF inhibitors and other immune-suppressive biologics have become the standard …
Rajesh Thippeshappa · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2022 · $378,000 — Abstract/Summary: Commonly used animal models of HIV-1 include infection of macaques with Simian Immunodeficiency Virus (SIV) or Simian-Human Immunodeficiency Virus (SHIV) containing HIV envelope (Env) or reverse transcriptase. These animal models have been extremely useful in understanding HIV path…
Roger Sciammas · UNIVERSITY OF CALIFORNIA-IRVINE · 2022 · $793,986 — Project summary: The vast majority of mammalian genes produce alternatively processed mRNAs through alternative splicing and alternative polyadenylation (APA). Different mRNA isoforms produced from the same gene can encode distinct proteins and/or they may be differentially regulated. Recent studies…
Natalie Lea Silver · CLEVELAND CLINIC LERNER COM-CWRU · 2022 · $155,304 — PROJECT SUMMARY/ABSTRACT Oral cavity squamous cell carcinoma (OCSCC) is a very aggressive and deadly disease with poor survival rates following maximal treatments such as surgery and chemoradiotherapy. The immunosuppressive tumor microenvironment (TME) is a major barrier of response to traditional …
Zachary Scott Morris · UNIVERSITY OF WISCONSIN-MADISON · 2022 · $765,000 — ABSTRACT We are developing a combined modality therapeutic approach to eradicating metastatic cancers that are immunologically “cold” and do not respond to immune checkpoint inhibition (ICI). Using an “in situ vaccine” regimen consisting of 12 Gy focal external beam radiation therapy (EBRT) and int…
EDWARD CHU · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2022 · $431,130 — Abstract It is now well-established that COVID-19 in patients with cancer carries a higher morbidity and mortality, especially in amongst patients with hematologic malignancies1, 2. Effective vaccines have been developed and authorized by the FDA to combat this pandemic3-5. However, emerging data su…
PAUL JOSEPH UTZ · STANFORD UNIVERSITY · 2022 · $329,868 — PROJECT SUMMARY/ABSTRACT The overarching goal of this R21 proposal is to test the hypothesis that DNA vaccines induce durable innate memory in HIV-infected humans by characterizing the evolution of the epigenetic and transcriptional landscape in subjects who have been immunized using a novel HIV DNA…
You Li · UNIV OF NORTH CAROLINA CHAPEL HILL · 2022 · $194,375 — PROJECT SUMMARY/ABSTRACT Hepatitis A virus (HAV), a plus-strand virus classified in the Picornaviridae, is a common cause of acute hepatitis. Despite the availability of vaccines, striking increases in the incidence of hepatitis A have led to increasing numbers of deaths associated with severe infec…
Colleen M. Lau · CORNELL UNIVERSITY · 2022 · $162,000 — PROJECT SUMMARY The candidate, Dr. Colleen Lau seeks to achieve an academic career as an independent research investigator at an institution where she can foster academic growth and immunology research that advances treatment or prevention of human disease. She aims to do so through a union of labo…
Isaac Jonathan Krauss · BRANDEIS UNIVERSITY · 2022 · $525,019 — Project Summary/Abstract Extensive study of HIV+ individuals in recent years has brought to light many examples of antibodies that can neutralize a broad range of HIV strains and protect against viral challenge in animal models of infection. The portion of viral surface most commonly targeted by suc…
Alexander Bukreyev · UNIVERSITY OF TEXAS MED BR GALVESTON · 2022 · $756,658 — PROJECT SUMMARY/ABSTRACT The Marburg virus (MARV) and Ravn virus (RAVV), which both belong to the genus Marburgvirus of the family Filoviridae, cause the severe disease in humans, with case fatality rates up to 90%. There are no licensed vaccines against marburgviruses. Clinical trials of vaccine ca…
Jordan Green · JOHNS HOPKINS UNIVERSITY · 2022 · $245,625 — PROJECT SUMMARY Multiple sclerosis (MS) is the leading cause of non-traumatic disability in young adults in the United States. In MS, the immune system attacks autoantigens in the myelin sheath of the central nervous system (CNS), leading to neurological degeneration, and there is currently no cure…
Shane P Crotty · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2022 · $779,142 — Project Summary Preclinical studies and early stage human trials evaluating passively transferred broadly neutralizing antibodies (bnAbs) suggest that a vaccine capable of eliciting bnAbs would provide effective protection from HIV infection. However, the difficulty of inducing bnAbs through vaccina…